High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
HemaSphere · 2024-12 · 8 (12)
DOI: 10.1002/hem3.70031 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 10.12.2024. Verfasst von Veronica González-Calle und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study examines the impact of cytogenetic abnormalities and their co‐segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM‐PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p), +1q, and del(1p), were investigated using FISH on CD38 purified plasma cells. The frequency of genetic alterations detected were as follows: del(17p) in 8%, t(4;14) in 12%, t(14;16) in 3%, +1q in 43%, and del(1p) in 8%. The median follow‐up was 61 months, and the median progression‐free survival (PFS) and overall survival (OS) were 44 months and not reached, respectively. Consistent with previous reports, the presence of t(4;14) was associated with shorter PFS and OS. In our series, the presence of t(14;16) did not impact survival, maybe due to limitations in sample size. Del(17p) was linked to poor prognosis using a cut‐off level of ≥20% positive cells, without any impact of higher cut‐off in prognosis, except for patients with clonal fraction ≥80% who had a dismal outcome. Cosegregation of cytogenetic abnormalities patients worsened the prognosis in t(4;14) patients but not in patients with del(17p), which retained its adverse prognosis even as a solitary abnormality. Gain(1q) was associated with significantly shorter PFS and OS, while del(1p) affected PFS but not OS. Nevertheless, when co‐segregation was eliminated, the detrimental effect of +1q or del(1p) was no longer observed. In conclusion, this study confirms the prognostic significance of high‐risk cytogenetic abnormalities in MM and highlights the importance of considering co‐occurrence for accurate prognosis assessment.
Autor:innen und Institutionen
- Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC) CIBERONC Salamanca Spain.
- Department of Hematology, Cancer Center Clinica Universidad de Navarra, CCUN, Centro de Investigacion Medica Aplicadas (Cima); Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBERONC Pamplona Spain.
- Department of Hematology, Hospital Universitario 12 de Octubre, I + 12, CNIO Complutense University, CIBERONC Madrid Spain.
- Department of Hematology, Hospital Clínic IDIBAPS Barcelona Spain.
- Department of Hematology Hospital Universitario de Canarias Tenerife Spain.
- Department of Hematology Hospital Clínico de Valencia Valencia Spain.
ORCID-Profile: Paula Rodriguez-Otero, Felipe de Arriba
Zitieren
APA
González-Calle, V., Rodriguez-Otero, P., Calasanz, M. J., Guijarro, M., Martínez-López, J., Rosiñol, L., Hernández, M. T., Teruel, A. I., Gironella, M., Oriol, A., de la Rubia, J., González-Rodríguez, A. P., Bargay, J., de Arriba, F., Palomera, L., González-Pérez, M. S., Sureda, A., Ocio, E., Lahuerta, J. J., …, & Gutiérrez, N. C. (2024). High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience. HemaSphere, 8(12). https://doi.org/10.1002/hem3.70031
Vancouver
González-Calle V, Rodriguez-Otero P, Calasanz MJ, Guijarro M, Martínez-López J, Rosiñol L, et al. High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience. HemaSphere. 2024;8(12). doi:10.1002/hem3.70031
BibTeX
@article{GonzlezCalle2024,
author = {González-Calle, Veronica and Rodriguez-Otero, Paula and Calasanz, Maria J and Guijarro, Manuela and Martínez-López, Joaquin and Rosiñol, Laura and Hernández, Miguel T and Teruel, Ana I and Gironella, Mercedes and Oriol, Albert and de la Rubia, Javier and González-Rodríguez, Ana P and Bargay, Joan and de Arriba, Felipe and Palomera, Luis and González-Pérez, Marta-Sonia and Sureda, Anna and Ocio, Enrique and Lahuerta, Juan J and Bladé, Joan and San Miguel, Jesus F and Mateos, Maria V and Gutiérrez, Norma C},
title = {High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience},
journal = {HemaSphere},
year = {2024},
volume = {8},
number = {12},
doi = {10.1002/hem3.70031}
}
EUVIMED